^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    GIGYF2 (GRB10 Interacting GYF Protein 2)

    i
    Other names: GRB10 Interacting GYF Protein 2, PERQ Amino Acid-Rich With GYF Domain-Containing Protein 2, Parkinson Disease (Autosomal Recessive, Early Onset) 11, Trinucleotide Repeat-Containing Gene 15 Protein, PERQ Amino Acid Rich, With GYF Domain 3, GRB10-Interacting GYF Protein 2, TNRC15, PERQ2, GYF2, PERQ Amino Acid Rich, With GYF Domain 2, Trinucleotide Repeat Containing 15, GYF Domain Containing 2, PARK11, GIGYF2, PERQ3
    Associations

    News

    Trials
    4ms
    RNA-binding protein GIGYF2 promotes colorectal cancer progression through activation of the METTL3/SERP1/STAT3 axis in an m6A-IGF2BP2-dependent manner. (PubMed, Biochem Pharmacol)
    In conclusion, our findings reveal a novel oncogenic pathway driven by GIGYF2, which activates the METTL3/SERP1/STAT3 axis in an m6A-IGF2BP2-dependent manner to enhance the proliferation and migration of cancer cells, contributing to CRC progression. This study may provide a potential prognostic marker and therapeutic target for CRC.
    Journal
    |
    GIGYF2 (GRB10 Interacting GYF Protein 2) • IGF2BP2 (Insulin Like Growth Factor 2 MRNA Binding Protein 2) • METTL3 (Methyltransferase Like 3)
    over1year
    Ribosome Quality Control mitigates the cytotoxicity of ribosome collisions induced by 5-Fluorouracil. (PubMed, Nucleic Acids Res)
    Furthermore, 5FU treatment enhances the expression of the key RQC factors ZNF598 and GIGYF2 via an mTOR-dependent post-translational mechanism. This adaptation likely mitigates the cytotoxic consequences of increased ribosome collisions upon 5FU treatment.
    Journal
    |
    TYMS (Thymidylate Synthetase) • GIGYF2 (GRB10 Interacting GYF Protein 2)
    |
    GIGYF2 overexpression
    |
    5-fluorouracil
    over1year
    RNA-binding protein GIGYF2 orchestrates hepatic insulin resistance through STAU1/PTEN-mediated disruption of the PI3K/AKT signaling cascade. (PubMed, Mol Med)
    Our study discloses that GIGYF2 mediates obesity-related IR by disrupting the PI3K/AKT signaling axis through the up-regulation of STAU1/PTEN. Targeting GIGYF2 may offer a potential strategy for treating obesity-related metabolic diseases, including type 2 diabetes.
    Journal
    |
    PTEN (Phosphatase and tensin homolog) • GIGYF2 (GRB10 Interacting GYF Protein 2)
    almost2years
    Comprehensive DNA methylation profiling by MeDIP-NGS identifies potential genes and pathways for epithelial ovarian cancer. (PubMed, J Ovarian Res)
    POLR3B and GIGYF2 turned out to be the novel genes associated with the carcinogenesis of EOC. Our study demonstrated that methylation profiling through MeDIP-sequencing has effectively identified six potential hub genes and pathways that might exacerbate our understanding of underlying molecular mechanisms of ovarian carcinogenesis.
    Journal • Next-generation sequencing • Epigenetic controller
    |
    CRKL (CRK Like Proto-Oncogene, Adaptor Protein) • GIGYF2 (GRB10 Interacting GYF Protein 2) • BMP2 (Bone Morphogenetic Protein 2)
    |
    GIGYF2 overexpression
    almost3years
    Comprehensive genomic characterization of early-stage bladder cancer from 438 patients by whole genome- and exome sequencing (AACR 2023)
    Here we investigated the landscape of DNA alterations in NMIBC in a large patient cohort of NMIBC samples with paired transcriptomic data and detailed clinical follow-up. We identified several novel genomic alterations; specifically, we showed that 15% of the tumors had genome doublings, and we identified a complex underlying copy number landscape of the region containing FGFR3.
    Clinical • Tumor mutational burden
    |
    HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • FGFR3 (Fibroblast growth factor receptor 3) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • CCND1 (Cyclin D1) • KMT2D (Lysine Methyltransferase 2D) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • ERCC2 (Excision repair cross-complementation group 2) • KMT2C (Lysine Methyltransferase 2C) • KDM6A (Lysine Demethylase 6A) • STAG2 (Stromal Antigen 2) • EP300 (E1A binding protein p300) • GIGYF2 (GRB10 Interacting GYF Protein 2)
    |
    TP53 mutation • HER-2 mutation • CDKN2A deletion • KMT2D mutation • RB1 mutation • CCND1 amplification • KDM6A mutation • EP300 mutation • GIGYF2 overexpression